These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7780482)

  • 1. Interleukin-15 and the growth of tumor derived activated T-cells.
    Lewko WM; Smith TL; Bowman DJ; Good RW; Oldham RK
    Cancer Biother; 1995; 10(1):13-20. PubMed ID: 7780482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth of tumor derived activated T-cells for the treatment of cancer.
    Lewko WM; Good RW; Bowman D; Smith TL; Oldham RK
    Cancer Biother; 1994; 9(3):211-24. PubMed ID: 7820183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth of tumor-derived activated T cells for the treatment of advanced cancer.
    Lewko WM; Hall PB; Oldham RK
    Cancer Biother Radiopharm; 2000 Aug; 15(4):357-66. PubMed ID: 11041020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
    Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
    Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma.
    Lotze MT; Zeh HJ; Elder EM; Cai Q; Pippin BA; Rosenstein MM; Whiteside TL; Herberman R
    J Immunother (1991); 1992 Oct; 12(3):212-7. PubMed ID: 1359903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15.
    Seder RA; Grabstein KH; Berzofsky JA; McDyer JF
    J Exp Med; 1995 Oct; 182(4):1067-77. PubMed ID: 7561680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma.
    Steger GG; Kaboo R; deKernion JB; Figlin R; Belldegrun A
    Br J Cancer; 1995 Jul; 72(1):101-7. PubMed ID: 7599037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory effects of interleukin-4 on tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
    Peyret C; Bochner BH; Lee TY; Koo AS; deKernion JB; Belldegrun A
    J Surg Res; 1992 Dec; 53(6):602-9. PubMed ID: 1494294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human T cells and interleukin 4 inhibit the release of interleukin 1 induced by lipopolysaccharide in serum-free cultures of autologous monocytes.
    Weiss L; Haeffner-Cavaillon N; Laude M; Cavaillon JM; Kazatchkine MD
    Eur J Immunol; 1989 Jul; 19(7):1347-50. PubMed ID: 2668014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.
    Perussia B; Chan SH; D'Andrea A; Tsuji K; Santoli D; Pospisil M; Young D; Wolf SF; Trinchieri G
    J Immunol; 1992 Dec; 149(11):3495-502. PubMed ID: 1358972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC).
    Oldham RK; Lewko WM; Good RW; Sharp E
    In Vivo; 1994; 8(5):653-63. PubMed ID: 7537108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
    Ioannides CG; Rashed S; Fisk B; Fan D; Itoh K; Freedman RS
    Lymphokine Cytokine Res; 1991 Aug; 10(4):307-15. PubMed ID: 1932375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis.
    Sebbag M; Parry SL; Brennan FM; Feldmann M
    Eur J Immunol; 1997 Mar; 27(3):624-32. PubMed ID: 9079801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
    Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA
    J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor.
    Santoli D; Clark SC; Kreider BL; Maslin PA; Rovera G
    J Immunol; 1988 Jul; 141(2):519-26. PubMed ID: 3290340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.
    Steger GG; Gnant MF; Djavanmard MP; Mader RM; Jakesz R; Pierce W; deKernion JB; Figlin R; Belldegrun A
    J Cancer Res Clin Oncol; 1997; 123(6):317-24. PubMed ID: 9222297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.